These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33371853)

  • 21. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
    Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
    Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence by Computed Tomographic Angiography of Coronary Plaques in South Asian and White Patients With Type 2 Diabetes Mellitus at Low and High Risk Using Four Cardiovascular Risk Scores (UKPDS, FRS, ASCVD, and JBS3).
    Gobardhan SN; Dimitriu-Leen AC; van Rosendael AR; van Zwet EW; Roos CJ; Oemrawsingh PV; Kharagjitsingh AV; Jukema JW; Delgado V; Schalij MJ; Bax JJ; Scholte AJ
    Am J Cardiol; 2017 Mar; 119(5):705-711. PubMed ID: 28024655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation.
    Hanif W; Ali SN; Bellary S; Patel V; Farooqi A; Karamat MA; Saeed M; Sivaprasad S; Patel K; Khunti K
    Diabet Med; 2021 Apr; 38(4):e14497. PubMed ID: 33301625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes.
    Khunti K; Bellary S; Karamat MA; Patel K; Patel V; Jones A; Gray J; Shepherd P; Hanif W;
    Diabet Med; 2017 Jan; 34(1):64-68. PubMed ID: 26926478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study.
    Webb DR; Gray LJ; Khunti K; Srinivasan B; Taub N; Campbell S; Barnett J; Farooqi A; Echouffo-Tcheugui JB; Griffin SJ; Wareham NJ; Davies MJ
    Diabetologia; 2011 Sep; 54(9):2237-46. PubMed ID: 21638133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Davis TME; Mulder H; Lokhnygina Y; Aschner P; Chuang LM; Raffo Grado CA; Standl E; Peterson ED; Holman RR;
    Diabetes Obes Metab; 2018 Jun; 20(6):1427-1434. PubMed ID: 29405540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.
    Kim YG; Hahn S; Oh TJ; Kwak SH; Park KS; Cho YM
    Diabetologia; 2013 Apr; 56(4):696-708. PubMed ID: 23344728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher insulin and glucagon-like peptide-1 (GLP-1) levels in healthy, young South Asians as compared to Caucasians during an oral glucose tolerance test.
    Sleddering MA; Bakker LE; Janssen LG; Meinders AE; Jazet IM
    Metabolism; 2014 Feb; 63(2):226-32. PubMed ID: 24290838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.
    Kim YG; Hahn S; Oh TJ; Park KS; Cho YM
    Diabetes Obes Metab; 2014 Oct; 16(10):900-9. PubMed ID: 24655583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.